Unresectable Intermediate-Size (3-5 cm) Colorectal Liver Metastases: Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation (COLLISION-XL): Protocol of a Phase II/III Multicentre Randomized Controlled Trial.
Articolo
Data di Pubblicazione:
2023
Citazione:
Unresectable Intermediate-Size (3-5 cm) Colorectal Liver Metastases: Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation (COLLISION-XL): Protocol of a Phase II/III Multicentre Randomized Controlled Trial / Van Der Lei, S; Dijkstra, M; Nieuwenhuizen, S; Schulz, Hh; Vos, Djw; Versteeg, Ks; Buffart, Te; Swijnenburg, Rj; De Vries, Jjj; Bruynzeel, Ame; Van Den Tol, Mp; De Cobelli, Francesco; Scheffer, Hj; Puijk, Rs; Haasbeek, Cja; Meijerink, Mr; And Collision Trial, Group. - In: CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY. - ISSN 0174-1551. - 46:8(2023), pp. 1076-1085. [10.1007/s00270-023-03498-8]
Abstract:
Background: Although microwave ablation (MWA) has a low complication rate and good efficacy for small-size (≤ 3 cm) colorectal liver metastases (CRLM), local control decreases with increasing size. Stereotactic body radiotherapy (SBRT) is gaining interest as a potential means to treat intermediate-size CRLM and might be less susceptible to increasing volume. The objective of this study is to compare the efficacy of MWA to SBRT in patients with unresectable, intermediate-size (3–5 cm) CRLM. Methods: In this two-arm, multicentre phase II/ III randomized controlled trial, 68 patients with 1–3 unresectable, intermediate-size CRLM suitable for both MWA and SBRT, will be included. Patients will be treated with MWA or SBRT as randomised. The Primary endpoint is local tumour progression-free survival (LTPFS) at 1 year (intention-to-treat analysis). Main secondary endpoints are overall survival, overall and distant progression-free survival (DPFS), local control (LC) and procedural morbidity and mortality and assessment of pain and quality of life. Discussion: Current guidelines lack clear recommendations for the local treatment of liver only intermediate-size, unresectable CRLM and studies comparing curative intent SBRT and thermal ablation are scarce. Although safety and feasibility to eradicate tumours ≤ 5 cm have been established, both techniques suffer from lower LTPFS and LC rates for larger-size tumours. For the treatment of unresectable intermediate-size CRLM clinical equipoise has been reached. We have designed a two-armed phase II/ III randomized controlled trial directly comparing SBRT to MWA for unresectable CRLM 3–5 cm. Level of Evidence : Level 1, phase II/ III Randomized controlled trial. Trial Registration: NCT04081168, September 9th 2019. Graphical Abstract: [Figure not available: see fulltext.]
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Van Der Lei, S; Dijkstra, M; Nieuwenhuizen, S; Schulz, Hh; Vos, Djw; Versteeg, Ks; Buffart, Te; Swijnenburg, Rj; De Vries, Jjj; Bruynzeel, Ame; Van Den Tol, Mp; De Cobelli, Francesco; Scheffer, Hj; Puijk, Rs; Haasbeek, Cja; Meijerink, Mr; And Collision Trial, Group
Link alla scheda completa:
Link al Full Text:
Pubblicato in: